Latest Headlines

Latest Headlines

UPDATED: Onyx sets out to spark a bidding war following $10B Amgen offer

A little more than a day after the Financial Post broke the story that Amgen had bid $120 a share for Onyx Pharmaceuticals, the biotech company has confirmed the offer and put the company up on the auction block.

Bayer, Raptor reel in endorsements from EMA for new therapies

The European Medicines Agency's experts have backed approval for two drugs that have already gained green lights for the U.S. market.

FDA sends J&J CRL on Xarelto for stent thrombosis

The FDA keeps offering up tough news to Johnson & Johnson for its warfarin replacement, Xarelto. It has twice turned it down for treatment of acute coronary syndrome (ACS), and today the company said it had a complete response letter for use of the bloodthinner to prevent stent thrombosis in patients with ACS.

Bayer, Boehringer eye big growth in expanding anticoagulant market

The U.K.'s cost-effectiveness watchdog gave final clearance to Bayer's anticoagulant drug Xarelto for use in preventing potentially fatal blood clots in the lungs and legs. Meanwhile, Boehringer Ingelheim was filing for European approval for its new-generation anticoagulant, Pradaxa, for similar uses.

Bayer beefs up cancer drug pipeline with $520M armed antibody deal with Seattle Genetics

Seattle Genetics, which has a who's who in oncology drug development signed on as ADC collaborators, gets $20 million of that upfront with the rest in milestones.

Bayer closes $1.1B birth control device deal

Bayer has wrapped up its $1.1 billion acquisition of Conceptus, adding the company's permanent birth control device to its flagging contraceptive business.

Bayer's Nexavar hits the brakes on thyroid cancer progression

Bayer and Onyx appear poised to expand sales of Nexavar (sorafenib). Investigators told the crowd at ASCO Sunday morning that their therapy almost doubled progression-free survival of treatment-resistant thyroid cancer patients, from a median 5.8 months in the control arm to 10.8 months in the treatment group.

Bayer wins NICE backing for fast-growing Lucentis challenger, Eylea

Bayer and Regeneron's hard-charging eye drug has traded its way to another victory. It won a recommendation from the U.K.'s cost-effectiveness watchdogs, on the strength of a pricing discount. Previously rejected as too expensive, Eylea is now in line for routine use by Britain's National Health Service.

France backs down on Diane 35 suspension after latest European review

French health regulators say they'll usher Bayer's hormonal pill Diane 35 back onto the market, if top European watchdogs ratify the latest recommendations from a drug-safety body.

Pfizer denies knowledge of acquired companies' failures in East German drug trials

As  Bloomberg  reports, Germany's  Der Spiegel  has ferreted more details about drug research in Soviet-era East Germany, where pharma groups tied to some of the biggest names in the industry reportedly benefited from cheap clinical trials before the fall of the Berlin Wall.